Statistik Asas
| LEI | 549300N6TVZB9N2Q9M78 |
| CIK | 1305253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eiger BioPharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| October 1, 2024 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36183 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as |
|
| October 1, 2024 |
EX-99.1 Exhibit 99.1 Case 24-80040-sgj11 Doc 685 Filed 09/30/24 Entered 09/30/24 20:53:07 Desc Main Document Page 1 of 5 SIDLEY AUSTIN LLP SIDLEY AUSTIN LLP William E. Curtin (admitted pro hac vice) Thomas R. Califano (TX Bar No. 24122825) Anne G. Wallice (admitted pro hac vice) 2021 McKinney Avenue, Suite 2000 787 Seventh Avenue Dallas, Texas 75201 New York, NY 10019 Telephone: (214) 981-330 |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) ( |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| September 9, 2024 |
Exhibit 2.1 Case 24-80040-sgj11 Doc 635-1 Filed 09/05/24 Entered 09/05/24 17:02:00 Desc Exhibit A Page 2 of 58 SIDLEY AUSTIN LLP SIDLEY AUSTIN LLP Thomas R. Califano (TX Bar No. 24122825) Charles M. Persons (TX Bar No. 24060413) William E. Curtin (admitted pro hac vice) 2021 McKinney Avenue, Suite 2000 Anne G. Wallice (admitted pro hac vice) Dallas, Texas 75201 787 Seventh Avenue Telephone: ( |
|
| September 9, 2024 |
Case 24-80040-sgj11 Doc 639 Filed 09/05/24 Entered 09/05/24 18:16:14 Desc Main Document Page 1 of 66 Exhibit 99.1 Case 24-80040-sgj11 Doc 639 Filed 09/05/24 Entered 09/05/24 18:16:14 Desc Main Document Page 1 of 66 Docket #0639 Date Filed: 09/05/2024 The following constitutes the ruling of the court and has the force and effect therein described. Signed September 5, 2024 IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION In re: EIGER BIOPHARMACEUTICALS |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| September 3, 2024 |
Exhibit 99.1 Case 24-80040-sgj11 Doc 582 Filed 08/30/24 Entered 08/30/24 15:16:15 Desc Main Document Page 1 of 12 UNITED STATES BANKRUPTCY COURT Northern DISTRICT OF Texas Dallas In Re. Eiger BioPharmaceuticals, Inc. § Case No. 24-80040 § § Lead Case No. 24-80040 Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Pe |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2024 |
EIGR / Eiger BioPharmaceuticals, Inc. / Arkin Moshe - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 28249U105 (CUSIP Number) August 19, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 2, 2024 |
Exhibit 10.1 Execution Version LONAFARNIB ASSET PURCHASE AGREEMENT by and between EIGER INNOTHERAPEUTICS, INC., as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of August 1, 2024 Table of Contents ARTICLE 1. DEFINED TERMS 1 1.1 Defined Terms 1 1.2 Other Definitional and Interpretive Matters 15 ARTICLE 2. THE PURCHASE AND SALE; CLOSING 17 2.1 Purchase and Sale 17 2.2 Excluded A |
|
| August 2, 2024 |
Exhibit 10.2 Execution Version LAMBDA ASSET PURCHASE AGREEMENT by and between EIGER INNOTHERAPEUTICS, INC., as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of August 1, 2024 TABLE OF CONTENTS ARTICLE 1. DEFINED TERMS 1 1.1 Defined Terms 1 1.2 Other Definitional and Interpretive Matters 12 ARTICLE 2. THE PURCHASE AND SALE; CLOSING 15 2.1 Purchase and Sale 15 2.2 Excluded Asse |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| August 1, 2024 |
Exhibit 99.1 Case 24-80040-sgj11 Doc 480 Filed 07/31/24 Entered 07/31/24 18:53:14 Desc Main Document Page 1 of 13 UNITED STATES BANKRUPTCY COURT Northern DISTRICT OF Texas Dallas In Re. Eiger BioPharmaceuticals, Inc. § Case No. 24-80040 § § Lead Case No. 24-80040 Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Pe |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| July 16, 2024 |
Case 24-80040-sgj11 Doc 424 Filed 07/15/24 Entered 07/15/24 21:34:38 Desc Main Document Page 1 of 52 EX-99.1 Case 24-80040-sgj11 Doc 424 Filed 07/15/24 Entered 07/15/24 21:34:38 Desc Main Document Page 1 of 52 Exhibit 99.1 SIDLEY AUSTIN LLP SIDLEY AUSTIN LLP Thomas R. Califano (TX Bar No. 24122825) Charles M. Persons (TX Bar No. 24060413) William E. Curtin (admitted pro hac vice) 2021 McKinney Avenue, Suite 2000 Anne G. Wallice (admitted pro hac vice) Dallas, Texas 75201 787 Seventh Avenue T |
|
| July 16, 2024 |
EX-99.2 Exhibit 99.2 Case 24-80040-sgj11 Doc 425 Filed 07/15/24 Entered 07/15/24 22:02:18 Desc Main Document Page 1 of 80 IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION In re: Chapter 11 EIGER BIOPHARMACEUTICALS INC., et al.1 Case No. 24-80040 (SGJ) (Jointly Administered) Debtors. DISCLOSURE STATEMENT FOR JOINT PLAN OF LIQUIDATION OF EIGER BIOPHARMAC |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commis |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| July 1, 2024 |
Exhibit 99.1 Case 24-80040-sgj11 Doc 385 Filed 06/28/24 Entered 06/28/24 19:12:34 Desc Main Document Page 1 of 12 UNITED STATES BANKRUPTCY COURT Northern DISTRICT OF Texas Dallas In Re. Eiger BioPharmaceuticals, Inc. § Case No. 24-80040 § § Lead Case No. 24-80040 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2024 Petition Date: 04/01/2024 Months |
|
| July 1, 2024 |
EIGR / Eiger BioPharmaceuticals, Inc. / Arkin Moshe - SC 13D/A Activist Investment SC 13D/A 1 zk2431622.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of class of securities) 28249U105 (CUSIP number) Moshe Arkin 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel Telephone: 972-972-9-78 |
|
| June 21, 2024 |
Exhibit 10.1 Execution Copy ASSET PURCHASE AGREEMENT by and between Amylyx Pharmaceuticals, Inc., or a wholly owned subsidiary thereof, as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of June 21, 2024 Table of Contents Page ARTICLE 1. DEFINED TERMS 1 1.1 Defined Terms 1 1.2 Other Definitional and Interpretive Matters 11 ARTICLE 2. THE PURCHASE AND SALE; CLOSING 13 2.1 Purchase |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2024 |
Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT by and between SPRUCE BIOSCIENCES, INC., as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of June 13, 2024 Table of Contents Page SCHEDULES Schedule 1.1(a) Permitted Liens Schedule 2.1(a) Transferred Inventory Schedule 2.1(b) Assigned Contracts Schedule 2.11 Preliminary Allocation Schedule Schedule 3.3 Seller Conflict; Req |
|
| May 28, 2024 |
Case 24-80040-sgj11 Doc 288 Filed 05/24/24 Entered 05/24/24 19:17:29 Desc Main Document Page 1 of 12 Exhibit 99.1 Case 24-80040-sgj11 Doc 288 Filed 05/24/24 Entered 05/24/24 19:17:29 Desc Main Document Page 1 of 12 Docket #0288 Date Filed: 05/24/2024 UNITED STATES BANKRUPTCY COURT Northern DISTRICT OF Texas Dallas In Re. Eiger BioPharmaceuticals, Inc. § Case No. 24-80040 § § Lead Case No. 24-80040 Debtor(s) § ☒ Jointly Admi |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2024 |
EIGRQ / Eiger BioPharmaceuticals, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #7 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U204 (CUSIP Number) April 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| May 10, 2024 |
EX-99.I 2 d838097dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| May 10, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d838097dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated May 10, 2024 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. Each of Columbia Seligman Technology and Information Fund and Columbia Management Investment Advisers, LLC author |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commiss |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| April 29, 2024 |
Exhibit 10.30 EIGER BIOPHARMACEUTICALS, INC. AMENDED 2021 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (this “Plan”) of Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsi |
|
| April 8, 2024 |
Exhibit 97.1 EIGER BIOPHARMACEUTICALS, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Eiger BioPharmaceuticals, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-361 |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 10.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT by and between SENTYNL THERAPEUTICS, INC., as Purchaser, and EIGER BIOPHARMACEUTICALS, INC., as Seller Dated as of March 31, 2024 Table of Contents Page ARTICLE 1. DEFINED TERMS 2 1.1 Defined Terms 2 1.2 Other Definitional and Interpretive Matters 12 ARTICLE 2. THE PURCHASE AND SALE; CLOSING 15 2.1 Purchase and Sale 15 2.2 Excluded Assets 1 |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transit |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 99.1 Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted Palo Alto, Calif., April 1, 2024 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection und |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2024 |
EIGR / Eiger BioPharmaceuticals, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #6 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. Each of Columbia Seligman Technology and Information Fund and Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial |
|
| February 14, 2024 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| January 8, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EIGER BIOPHARMACEUTICALS, INC. Eiger BioPharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The original Certificate of Incorporation of the Corporation was filed |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| January 4, 2024 |
Eiger BioPharmaceuticals, Inc. Announces EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split Palo Alto, Calif., January 4, 2024 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the “Company”), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outsta |
|
| December 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| December 4, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Arkin Moshe - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of class of securities) 28249U105 (CUSIP number) Moshe Arkin 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel Telephone: 972-972-9-7883330 with a copy to: Goldfarb Gro |
|
| December 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| November 24, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Arkin Moshe - SC 13D Activist Investment SC 13D 1 zk2330592.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of class of securities) 28249U105 (CUSIP number) Jim Harding 1900 Avenue of the Stars, #1000 Los Angeles, CA 90067 908-507-9629 Mark Morski 1900 Avenue of th |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2023 |
Exhibit 10.2 CONFIDENTIAL September 21, 2023 Ingrid Choong Senior Vice President, Clinical Development Dear Ingrid, Eiger is very pleased to offer you a promotion to Chief Business Officer reporting directly to David Apelian, Chief Executive Officer. Your new responsibilities are outlined in the attached job description. Your remote position will continue to be headquartered at 2155 Park Blvd, Pal |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 9, 2023 |
Exhibit 99.1 Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update •Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications •Active discussions underway with potential partners to advance late-stage virology programs •Reduction in workforce executed to align with focus on avexitide; extends cash runway to into Q4 2024 •D |
|
| November 9, 2023 |
Exhibit 10.1 25 November 2019 Eiger BioPharmaceuticals, Inc. 2155 Park Boulevard Palo Alto, CA 94306 Ingrid Choong, Ph.D. Re: Employment Terms Dear Dr. Choong, Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) is pleased to offer the following terms to govern your continued employment in this Letter Agreement (“Agreement”). Duties, Compensation and Benefits You will continue to serve as th |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2023 |
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update •Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications •Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings •Company’s cash runway expected to extend into the third quarter of 2024 Palo Alto, Calif. |
|
| November 3, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Propel Bio Management, LLC - SC 13D/A Activist Investment SC 13D/A 1 ef20013959sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Eiger Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 282 49U 105 (CUSIP Number) Jim Harding 1900 Avenue of the Stars, #1000 Los Angeles, CA 90067 908-507-96 |
|
| October 20, 2023 |
EX-99.1 2 ef20012872ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock, par value $0.001 per share, of Eiger BioPharmaceuticals, Inc., a Delaware corp |
|
| October 20, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Propel Bio Management, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Eiger Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 282 49U 105 (CUSIP Number) Jim Harding 1900 Avenue of the Stars, #1000 Los Angeles, CA 90067 908-507-9629 Mark Morski 1900 Avenue of the Stars, #1 |
|
| September 28, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Propel Bio Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EIGER BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) 9/14/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| September 12, 2023 |
EX-99.1 Exhibit 99.1 Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Palo Alto, Calif., September 12, 2023 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) ( |
|
| August 15, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Propel Bio Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EIGER BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) 8/02/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| August 14, 2023 |
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update •Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications •Active discussions underway with potential partners to advance late-stage virology programs •Reduction in workforce executed to align with focus on avexitide; extends cash runway to into Q4 2024 •David Apelian, MD, PhD, MBA, appointed CEO Palo Alto, Calif. |
|
| August 14, 2023 |
Exhibit 10.2 March 31, 2023 Jim Vollins Dear Jim, On behalf of Eiger BioPharmaceuticals, Inc. (the “Company”), I am pleased to confirm the terms and conditions of your offer of at-will employment, with an anticipated start date, Monday April 10, 2023 (“Start Date”), pursuant to this letter (this “Letter”). Assuming you satisfy the contingencies below, this Letter sets forth the terms and condition |
|
| August 14, 2023 |
Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of March 10, 2023 (the “Effective Date”), by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation, with a business address at 2155 Park Boulevard, Palo Alto, CA 94306 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal place of busin |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 28, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 30, 2023 |
EX-10.1 Exhibit 10.1 June 28, 2023 VIA ELECTRONIC MAIL David Apelian, MD, PhD, MBA Re: Amended and Restated Employment Terms Dear Dr. Apelian, You and Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) wish to enter into this Amended and Restated Employment Terms (“Agreement”), embodying the terms of your new role with the Company, and to replace in its entirety and supersede the terms of t |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2023 |
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update •Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 2023 •Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 2023 •Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated •Cash Position: $75. |
|
| April 26, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / Arkin Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 28249U105 (CUSIP Number) April 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| April 10, 2023 |
to Schedule 13G Joint Filing Agreement EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated April 10, 2023 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. Each of Columbia Seligman Technology and Information Fund, Seligman Tech Spectrum (Master) Fund and Columbia Management Investment Advisers, |
|
| April 10, 2023 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| April 10, 2023 |
EIGR / Eiger BioPharmaceuticals Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #5 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) February 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| March 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-361 |
|
| March 17, 2023 |
As filed with the Securities and Exchange Commission on March 17, 2023 S-8 As filed with the Securities and Exchange Commission on March 17, 2023 Registration No. |
|
| March 17, 2023 |
Exhibit 10.41 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is being entered into on the date listed on the signature page hereof by and between David Cory (“Executive”) and Eiger BioPharmaceuticals, Inc. (“Company”). Executive and the Company are referred to jointly as the “Parties” or individually as a “Party.” WHEREAS, Executive was employe |
|
| March 17, 2023 |
Exhibit 10.42 January 9, 2023 VIA ELECTRONIC MAIL ([email protected]) David Apelian, MD, PhD, MBA 3 Old Beach Glen Road Boonton, New Jersey 07005 Re: Interim CEO Employment Terms Dear Dr. Apelian, Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) is pleased to offer employment to you on the following terms of this Offer Letter Agreement (“Agreement”): Duties You will be employed as th |
|
| March 17, 2023 |
2023, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC. Exhibit 10.43 Second Amendment to Lease This Second Amendment to Lease (“Amendment”) is made and entered January 23, 2023 (the “Amendment Effective Date”) by and between McDonald Family Co. LLC (“Lessor”) and Eiger Pharmaceuticals, Inc. (“Lessee”). WHEREAS, Lessor and Lessee are parties to that certain Standard Multi-Tenant Office Lease – Net dated October 17, 2017, as amended with Addendum to Lea |
|
| March 17, 2023 |
Calculation of Filing Fee Table EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Eiger BioPharmaceuticals, Inc. |
|
| March 17, 2023 |
Eiger BioPharmaceuticals, Inc. Amended and Restated 2021 Inducement Plan. EX-99.3 Exhibit 99.3 EIGER BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN Approved by the Board of Directors: June 15, 2021 Amended by the Board of Directors: February 24, 2023 1. PURPOSE OF PLAN The purpose of this Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (this “Plan”) of Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the inter |
|
| March 16, 2023 |
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update •Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 •Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 •Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated •Cash Position: $98. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 5)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2022 |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| February 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 2, 2023 |
EIGR / Eiger Biopharmaceuticals Inc / Arkin Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 10, 2023 |
EX-99.I 2 d407273dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| January 10, 2023 |
EIGR / Eiger Biopharmaceuticals Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A 1 d407273dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #4 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) December 31,2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 10, 2023 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d407273dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated January 10,2023 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc.. Each of Columbia Seligman Technology and Information Fund and Columbia Management Investment Advisers, LLC au |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| December 8, 2022 |
EX-99.1 Exhibit 99.1 Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint • Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) • Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001) • Peginterferon alfa comparator ar |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2022 |
Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update ? Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in December ? Phase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling Patients ? Phase 3 Congenital Hyperinsulinism Avant (avexitide) Program Initiated ? Strong Cash Position: $121.0 Million in Cas |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| August 4, 2022 |
Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update ? Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application ? Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End ? Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated ? Approval of Zokinvy in Europe; Partnership with AnGes |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| June 7, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of June |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commis |
|
| June 7, 2022 |
Exhibit 10.2 EIGER BIOPHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?) is made as of June 1, 2022 (the ?Execution Date?) by and among Eiger BioPharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each an ?Investor,? and collectively the ?Investors?). RECITALS WHEREAS, |
|
| May 11, 2022 |
EIGR / Eiger Biopharmaceuticals Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #3 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) May 6, 2022 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| May 11, 2022 |
Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| May 11, 2022 |
to Schedule 13G Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated May 11, 2022 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2022 |
Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update • Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 • Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End • Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022 • Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Ye |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger Bio |
|
| May 2, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 28249U105 (CUSIP Number) April 21, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| April 28, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| March 25, 2022 |
EX-1.1 2 d315548dex11.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 25, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A |
|
| March 25, 2022 |
424B5 1 d319148d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251497 Prospectus Supplement (To Prospectus dated December 31, 2020) $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus supplement a |
|
| March 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2022 |
Exhibit 99.1 Eiger?s Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study ? Second largest study to date in COVID-19 outpatients (N=1,936) ? Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint ? 60% reduced risk of COVID-19-related dea |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
Exhibit 10.38 DEFAULT WAIVER AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS DEFAULT WAIVER AND FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 10, 2020, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in suc |
|
| March 10, 2022 |
Exhibit 99.1 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ? Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 ? Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 ? Phase 3 HDV LIMT-2 (Lambda) Study Enrolling ? Strong Cash Position of Approximately $106 Million as of 12/31/21 ? Company to Host Con |
|
| March 10, 2022 |
Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation EBPI Merger, Inc. Delaware EB Pharma LLC Delaware Eiger BioPharmaceuticals Europe Limited England and Wales EigerBio Europe Limited Ireland |
|
| March 10, 2022 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Eiger BioPharmaceuticals, Inc. |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36183 Eiger BioPharma |
|
| March 8, 2022 |
EIGR / Eiger Biopharmaceuticals Inc / Arkin Moshe - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 28249U105 (CUSIP Number) March 1, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 4)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2021 |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) Frank Kung Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address |
|
| January 21, 2022 |
to Schedule 13D Joint Filing Agreement Exhibit I to Schedule 13D Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13D dated January 21, 2022 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. |
|
| January 21, 2022 |
EIGR / Eiger Biopharmaceuticals Inc / AMERIPRISE FINANCIAL INC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) Columbia Management Investment Advisers Attn: Matthew Rich 290 Congress Street Boston, MA 02210 Tel: (617) 385-9572 (Name, Address and Telephone Numb |
|
| January 6, 2022 |
Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones Exhibit 99.1 Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones ? Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 ? Phase 3 HDV LIMT-2 (Peginterferon Lambda) Study Enrolling and Dosing ? Phase 3 COVID-19 TOGETHER (Peginterferon Lambda) Study Topline Data 1H22 ? Zokinvy MAA CHMP Opinion Expected 1H22 ? Strong Cash Position of Approximately |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| December 21, 2021 |
Exhibit 99.1 Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Palo Alto, Calif., December 21, 2021 / PRNewswire / ? Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure H |
|
| December 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| November 4, 2021 |
Exhibit 10.2 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of October 6, 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?) |
|
| November 4, 2021 |
Exhibit 99.1 Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) Enrolled; Topline Data Planned by End of 2022 - Phase 3 HDV LIMT-2 (Peginterferon Lambda) Enrolling - Company to Host Conference Call Today at 4:30 PM ET Palo Alto, Calif., November 4, 2021 /PRNewswire/ ? Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a c |
|
| November 4, 2021 |
Exhibit 10.1 August 26, 2021 Erik Atkisson 1648 Versailles Avenue Alameda, California 94501 Re:Employment Terms Dear Mr. Atkisson, Eiger BioPharmaceuticals, Inc. (?Eiger? or the ?Company?) is pleased to offer you employment on the following terms of this Offer Letter Agreement (?Agreement?). Duties, Compensation and Benefits You will serve as the General Counsel, Corporate Secretary, and Chief Com |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| September 10, 2021 |
to Schedule 13G Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated September 10, 2021 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. |
|
| September 10, 2021 |
Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| September 10, 2021 |
EIGR / Eiger Biopharmaceuticals Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) Frank Kung Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger BioP |
|
| August 5, 2021 |
Exhibit 10.1 EIGER BIOPHARMACEUTICALS, INC. 2021 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (this ?Plan?) of Eiger BioPharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries a |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2021 |
EX-99.1 2 d209255dex991.htm EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update • HDV Platform Strategy Rapidly Advancing • Phase 3 HDV D-LIVR (Lonafarnib) >90% Enrolled; On-Track for Full Enrollment in 2021 • Phase 3 HDV LIMT-2 (Lambda) On-Track for First Patient to Enroll in 2021 • All Five Rare Disease Programs Now Have Breakt |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021. As filed with the Securities and Exchange Commission on August 5, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EIGER BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 33-0971591 (State or other jurisdiction of incorporation or organization) |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger Bio |
|
| May 6, 2021 |
Exhibit 10.2 Eiger BioPharmaceuticals, Inc. Restricted Stock Unit Award Grant Notice 2013 Equity Incentive Plan Eiger BioPharmaceuticals, Inc. (the ?Company?) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Award Grant Notice |
|
| May 6, 2021 |
Exhibit 99.1 Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update ? Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 ? Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 ? Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm ? $3.6M U.S. Zokinvy? Net Sales in Q1 2021 Palo Alto, Calif., May 6, 2021 /PRNewswire/ ? Eige |
|
| April 29, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 Eiger BioPharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Comm |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| March 9, 2021 |
Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation EBPI Merger, Inc. Delaware EB Pharma LLC Delaware Eiger BioPharmaceuticals Europe Limited England and Wales EigerBio Europe Limited Ireland |
|
| March 9, 2021 |
Exhibit 10.31 Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN ABBVIE INC. AND EIGER BIOPHARMACEUTICALS, INC. NOVEMBER 20, 2020 Table of Contents Page Table ARTICLE 1 DEFINITIONS 1 1.1 Certain Definitions 1 ARTICLE 2 PURCHASE AND SALE; CLOSING 5 2.1 Purchase and Sale of Purchased Assets. 5 2.2 Purchase Price 6 2.3 Closing 6 2.4 Title Passage; Delivery of Purchased Assets. 6 2.5 Closing De |
|
| March 9, 2021 |
Exhibit 10.32 AMENDMENT #7 TO LICENSE AGREEMENT This Amendment #7 to License Agreement (?Amendment #7?) is entered into as of the date of last signature below (?Amendment #7 Effective Date?) by and between Merck Sharp & Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (?Merck?) and Eiger BioP |
|
| March 9, 2021 |
As filed with the Securities and Exchange Commission on March 9, 2021. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EIGER BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 33-0971591 (State or other jurisdiction of incorporation or organization) ( |
|
| March 9, 2021 |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36183 Eiger BioPharma |
|
| March 9, 2021 |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2021 |
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2021 |
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2021 |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2021 |
Exhibit 99.1 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update ? Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 ? Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 ? Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021 Palo Alto, Calif., March 9, 2021 /PRNewswire/ ? Eiger BioPharmaceuticals, Inc. (Nasdaq:E |
|
| March 9, 2021 |
Exhibit 10.33 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of February [], 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agen |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2020 (Date of |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 28249U105 (CUSIP Number) Frank Kung Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address |
|
| February 11, 2021 |
Eiger Biopharmaceuticals, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Eiger Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| January 11, 2021 |
EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated January 11, 2021 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is att |
|
| January 11, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 11, 2021 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| January 7, 2021 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| January 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| January 7, 2021 |
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans • Phase 3 HDV D-LIVR (Lonafarnib) Planned to Complete Enrollment in 2021 • Phase 3 HDV LIMT-2 (Lambda) Planned to Initiate in 2H21 • Zokinvy™ EMA Approval Expected in 2H21 • Strong Cash Position with ~$176M Pro Forma Cash to Begin 2021 Palo Alto, Calif., January 7, 2021 /PRNewswire/ — Eiger BioPharmaceuticals, In |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 28, 2020 |
CORRESP EIGER BIOPHARMACEUTICALS, INC. 2155 Park Boulevard Palo Alto, CA 94306 (877) 899-2051 December 28, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio Re: Eiger BioPharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 18, 2020 File No. 333-25 |
|
| December 18, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 4 d73885dex45.htm EX-4.5 Exhibit 4.5 EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EIGER BIOPHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [na |
|
| December 18, 2020 |
EX-4.3 3 d73885dex43.htm EX-4.3 Exhibit 4.3 EIGER BIOPHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Sec |
|
| December 18, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EIGER BIOPHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associat |
|
| December 18, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 5 d73885dex46.htm EX-4.6 Exhibit 4.6 EIGER BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF EIGER BIOPHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corpora |
|
| December 18, 2020 |
Open Market Sale AgreementSM, dated December 18, 2020, between the Company and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 18, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’ |
|
| December 18, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 18, 2020 Registration No. |
|
| November 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| November 23, 2020 |
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million • Eiger and The Progeria Research Foundation will share proceeds 50/50 • Non-dilutive capital further strengthens Eiger’s balance sheet PALO ALTO, Calif., November 23, 2020 / PRNewswire / — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies f |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2020 |
EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Palo Alto, Calif., November 5, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for third quarter 2020 and provided a |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| August 6, 2020 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 6, 2020 |
EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif., August 6, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for second quarter 2020 and provided a |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporati |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger BioP |
|
| August 6, 2020 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 6, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s c |
|
| August 6, 2020 |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. |
|
| June 17, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (C |
|
| May 29, 2020 |
DEFA14A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 19, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Co |
|
| May 19, 2020 |
Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PALO ALTO, Calif. May 19, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced tha |
|
| May 7, 2020 |
EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif., May 7, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Com |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36183 Eiger Bio |
|
| May 7, 2020 |
Exhibit 10.2 Eiger Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Eiger BioPharmaceuticals, Inc. (“Eiger”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Boar |
|
| May 7, 2020 |
Exhibit 10.1 December 3, 2019 Eiger BioPharmaceuticals, Inc. 2155 Park Boulevard Palo Alto, CA 94306 Mr. Eldon Mayer 15657 Shady Lane Los Gatos, California 95032 Re:Employment Terms Dear Mr. Mayer, Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) is pleased to offer you employment on the following terms of this Offer Letter Agreement (“Agreement”). Duties, Compensation and Benefits You wi |
|
| April 28, 2020 |
DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2020 |
DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2020 |
Exhibit 99.1 Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic - HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline - Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating PALO ALTO, Calif. April 1, 2020 - Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercializati |
|
| March 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) ( |
|
| March 13, 2020 |
EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update - Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA - Progeria NDA Submission Complete by End of March 2020 - Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:E |
|
| March 13, 2020 |
Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation EBPI Merger, Inc. Delaware EB Pharma LLC Delaware Eiger BioPharmaceuticals Europe Limited England and Wales EigerBio Europe Limited Ireland |
|
| March 13, 2020 |
EIGR / Eiger BioPharmaceuticals, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36183 Eiger BioPharma |
|
| March 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 EIGER BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36183 33-0971591 (State or other jurisdiction of incorporation) ( |
|
| March 13, 2020 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Eiger BioPharmaceuticals, Inc. (“we,” “our,” or “us,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share (the “common s |
|
| March 13, 2020 |
EIGR / Eiger BioPharmaceuticals, Inc. S-8 - - FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on March 13, 2020. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EIGER BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 33-0971591 (State or other jurisdiction of incorporation or organ |
|
| February 14, 2020 |
EIGR / Eiger BioPharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 14, 2020 |
EIGR / Eiger BioPharmaceuticals, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Eiger BioPharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 28249U105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
